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donor-reactive antibodies in kidney 
~ transplantation predispose to accelerated or precipi-
graft failure. sometimes within hours after transplan-
(hyperacute rejection). 1 However. liver allografts 
been shown to be resistant to this form of injury. 2 
Imrlm"enlenlts in surgical techniques, preservation meth-
. patient selection and management.3 as well as the 
Iiltl'O<illlctlLon of the new immunosuppressant. FK 506.4 
improved early liver allograft survival. reducing 
of the nonimmunologic causes of early graft dys-
This study was undertaken with consent on a subset of 
,p;iI.'~"'" previously reponed showing a deleterious effect 
lymphocytotoxic antibodies.s We wanted to determine 
effect. if any. of preformed lymphocytotoxic antibodies 
early liver allograft function and histology, and deter-
whether immunologic injury to the graft could be 
~det:ect:ed. The following is an overview of our results. to be 
;prcsellited in detail elsewhere.6 
'Dc"we.". November 31. 1989 and September 9. 1990.243 adult 
received primary liver allografts under FK 506 and 
~\101w~,ose steroid therapy. There were 26 (11%) patients who 
~rec:elVI~d crossmatch-positive primary hepatic grafts during this 
Fifty-two cross match-negative control patients were se-
on the basis of a sequential OL T number assigned to each 
during the same period of time. as previously described. 7 
No statistically significant difference in either sex. age. UNOS 
status. original disease. donor demographic data or cold ischemic 
between crossmatch-positive and control cases was de-
All patients received ABO-identical hepatic grafts. 
The recipient's sera obtained immediately before liver trans-
!plantallion were tested for cytotoxic antibody activity against T 
IVlnnh" .. v' .. c isolated from donor lymph node at room tempera-
(37"C) for 30 minutes followed by 60 minutes of incubation 
with rabbit complement. Target cell lysis was determined by 
trypan blue exclusion with dithioilireitol (Om treatment. ginter-
. preted as positive when more than 50% of lymphocytes were 
Clinical events of the patients were reviewed. and graft and 
patient survival were calculated by the life-table method of 
Kaplan·Meier. Differences in survival curves were measured 
. using the generalized Wilcoxon test. Statistical comparisons were 
by Student's r test and by chi-square analysis. 
Liver allograft biopsies were performed immediately before 
'~tmplarltatJion. after complete revascularization. and thereafter. 
clinically indicated. All routine H&E slides and selected 
biopsy and all failed allograft tissue specimens (stained for 
presence of IgG. IgM. IgA. Clq. C3. C4. a-2·macroglobulin. 
transferrin. and fibrinogen) were reviewed by two of the authors 
(K.N .. A.J.D.). 
RESULTS 
Early postoperative graft function was assessed by daily 
median values of platelet counts and standard liver func-
tion tests for both groups. The crossmatch-positive pa-
tients showed lower peripheral platelet counts and higher 
total bilirubin levels during the first 30 days than control 
patients. The canalicular enzymes were similar in the two 
groups. 
The incidence of clinically indicated needle biopsies 
performed during the first 10 days after surgery was 
significantly higher in the crossmatch-positive cases (77% 
vs 42%: P < .01). Employing previously published his-
tologic criteria.9 the diagnosis of acute cellular rejection 
was more common in the cross match-positive cases in the 
first 10 days (P < .05) and of "preservation" injury during 
the first 20 days. Also. the mean time for the first onset of 
cellular rejection was 9 ± 6 days in crossmatch-positive 
patients compared to 14 ± 6 days in the controls (P < .05). 
Other histologic findings with a statistically significant 
difference between the two groups included vascular plate-
let aggregation in postreperfusion biopsies (P < .05), 
neutrophilic ponal venulitis in the first 10 days (P < .05). 
and cholangiolar proliferation between 20 and 30 days 
(P < .05). 
Among the control group. 3 (6%) grafts failed within 180 
days, compared with 7 (27%) in the crossmatch-positive 
group. A statistically significant difference was seen for 
both primary graft (P < .01) and patient (P < .05) survival. 
In the crossmatch-positive patients. ponal inflammation 
with neutrophilia and cholangiolar proliferation. hepato-
cellular swelling, focal large hilar bile duct necrosis with 
biliary sludge, organized intrahepatic ponal vein. and 
anerial thrombi were common findings. Although necro-
tizing or neutrophilic aneritis was not seen, anerial find-
ings included a thickened media with medial myocyte 
vacuolization (indirect evidence of spasm) and marked 
endothelial cell hypenrophy. at times with platelet margin-
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ation coating the lumenal surface. At the time of this 
writing, nine of the crossmatch-positive patients and seven 
controls had died, but no differences in the causes of death 
were noted. 
Direct immunofluorescent analysis for immunoglobulin 
and complement deposition were detected only in samples 
taken immediately or shortly after transplantation and 
consisted of relatively faint granular IgG, Clq, and C3 
deposits. predominantly in the sinusoids. Focal weak 
deposits were detected in hepatic arteries, while portal and 
central veins were generally negative. No immune depos-
its were detected in any of the control cases examined. 
DISCUSSION 
The results of this study demonstrate that IgG Iymphocy-
totoxic antibodies can adversely influence human liver 
allograft function. Compared to patients without such 
antibodies. humorally sensitized patients in this series 
more frequently experienced early allograft dysfunction. 
for which they were subjected to needle biopsies. earlier 
and more often. These sensitized patients also suffered 
from an earlier onset and more frequent and relapsing 
episodes of acute cellular rejection. and risked earlier graft 
failure from apparent immunologic injury, which patholog-
ically resembled ischemic or "preservation" injury.s 
Recognition of the pattern of injury associated with 
Iymphocytotoxic antibodies on needle biopsy was ex-
tremely difficult to separate from "preservation" injury 
and sepsis, even in retrospect with the use of immunoflu-
orescent staining. This difficulty was highlighted by the 
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fact that a diagnosis of "preservation" injury was signifi. 
candy more common in the crossmatch-positive patients 
even though no difference in the cold ischemic time w~ 
appreciated. 
Although a deleterious effect of preformed antibodie ')n 
patient and graft survival was seen in this series. it ,"as 
relatively small compared to the experience in renal trans-
plantation. It is likely that the "protective" mechanisms of 
the liver account for this difference. 10 Furthermore. We 
have since adopted a more aggressive immunosuppressive 
regimen in presensitized liver allograft recipients, which is 
initiated immediately after transplantation. 
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